Table 1.

Baseline data

Contents	Observation group (n = 11)	Control group (n = 11)
Sex
Male	11 (100.0%)	10 (90.9%)
Female	0 (0.0%)	1 (9.1%)
Age (year)	24.4 ± 5.0	24.9 ± 5.4
BMI (kg/m2)	21.8 ± 3.0	19.9 ± 2.6
Volume of fat (mL)	48.4 ± 23.1	–
Number of cells (×106cells)	142.3 ± 45.7	–
Simplified CDAI†	4.3 ± 0.5	4.4 ± 0.7
PDAI*	8.5 ± 1.4	9.5 ± 1.7
IBDQ‡	143.5 ± 19.8	137.9 ± 29.7
VAS§	0.8 ± 1.0	1.1 ± 1.0
Wexner¶	1.2 ± 1.3	1.5 ± 0.7
Location of Crohn’s disease
Ileum (L1)	1 (9.1%)	1 (9.1%)
Colon (L2)	4 (36.4%)	3 (27.3%)
Ileocolon (L3)	6 (54.6%)	7 (63.6%)
Upper gastrointestinal (L4)	0 (0.0%)	0 (0.0%)
Classification of fistula-in-ano (Parks)
Transsphincteric	4 (36.4%)	7 (63.6%)
Suprasphincteric	1 (9.1%)	0 (0.0%)
Intersphincteric	4 (36.4%)	3 (27.3%)
Extrasphincteric	2 (18.2%)	1 (9.1%)
Number of internal openings
1	9 (81.8%)	10 (90.9%)
2	2 (18.2%)	1 (9.1%)
Number of external openings
1	5 (45.4%)	5 (45.4%)
2	3 (27.3%)	4 (36.4%)
3	2 (18.2%)	2 (18.2%)
4	1 (9.1%)	0 (0.0%)
Drug use at baseline
ASA	11/11 (100.0%)	11/11 (100.0%)
Probiotics	11/11 (100.0%)	11/11 (100.0%)
Immunomodulators	1/11 (9.1%)	3/11 (27.3%)
Antibiotics	1/11 (9.1%)	1/11 (9.1%)
Anti-TNF	0/11 (0.0%)	0/11 (0.0%)
Glucocorticoids	0/11 (0.0%)	0/11 (0.0%)

Data are mean (SD) or number (%). Percentages might not always add up to exactly 100% as a result of rounding. BMI = body mass index. ASA = aminosalicylic acid. TNF = tumor necrosis factor. †Scores Less than 4 is divided into remission period, 5–8 is divided into moderate active period, and more than 9 is divided into severe active period. *Scores range from 0 to 20; higher scores suggest more severe disease. ‡Scores range from 32 to 224; higher scores suggest better quality of life. §Scores range from 0 to 10; higher scores suggest more severe degree of pain. ¶Scores range from 0 to 20; higher scores suggest more severe degree of anal incontinence